Carol Lyn Armour

Carol Lyn Armour

Auto-generated profile, based on publicly available information

Carol Lyn Armour

Woolcock Institute of Medical Research, Glebe, Australia

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in Molecular Immunology
Verified
Journal Article
Closed access
ZIZaridatul Aini Ibrahim
Zaridatul Aini Ibrahim
CACarol L. Armour
Carol L. Armour
SPSimon Phipps
Simon Phipps
MSMaria Sukkar
Maria Sukkar

1 June 2007 in Thorax
Verified
Journal Article
Closed access
CAC. Armour
C. Armour
SBS. Bosnic-Anticevich
S. Bosnic-Anticevich
MBM. Brillant
M. Brillant
DBD. Burton
D. Burton
LELynne Emmerton
Lynne Emmerton
KSK. Stewart
K. Stewart
Despite national disease management plans, optimal asthma management remains a challenge in Australia. Community pharmacists are ideally placed to implement new strategies that aim to ensure asthma care meets current standards of best practice. The impact of the Pharmacy Asthma Care Program (PACP) on asthma control was assessed using a multi-site randomised intervention versus control repeated measures study design. Fifty Australian pharmacies were randomised into two groups: intervention pharmacies implemented the PACP (an ongoing cycle of assessment, goal setting, monitoring and review) to 191 patients over 6 months, while control pharmacies gave their usual care to 205 control patients. Both groups administered questionnaires and conducted spirometric testing at baseline and 6 months later. The main outcome measure was asthma severity/control status. 186 of 205 control patients (91%) and 165 of 191 intervention patients (86%) completed the study. The intervention resulted in improved asthma control: patients receiving the intervention were 2.7 times more likely to improve from "severe" to "not severe" than control patients (OR 2.68, 95% CI 1.64 to 4.37; p<0.001). The intervention also resulted in improved adherence to preventer medication (OR 1.89, 95% CI 1.08 to 3.30; p = 0.03), decreased mean daily dose of reliever medication (difference -149.11 microg, 95% CI -283.87 to -14.36; p=0.03), a shift in medication profile from reliever only to a combination of preventer, reliever with or without long-acting beta agonist (OR 3.80, 95% CI 1.40 to 10.32; p=0.01) and improved scores on risk of non-adherence (difference -0.44, 95% CI -0.69 to -0.18; p=0.04), quality of life (difference -0.23, 95% CI -0.46 to 0.00; p=0.05), asthma knowledge (difference 1.18, 95% CI 0.73 to 1.63; p<0.01) and perceived control of asthma questionnaires (difference -1.39, 95% CI -2.44 to -0.35; p<0.01). No significant change in spirometric measures occurred in either group. A pharmacist-delivered asthma care programme based on national guidelines improves asthma control. The sustainability and implementation of the programme within the healthcare system remains to be investigated.

1 June 2007 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
IBIman A. Basheti
Iman A. Basheti
HRHelen K. Reddel
Helen K. Reddel
CACarol L. Armour
Carol L. Armour
SBSinthia Z. Bosnic-Anticevich
Sinthia Z. Bosnic-Anticevich

22 May 2007 in Diabetic Medicine
Verified
Journal Article
Closed access
PDF file
IKI. Krass
I. Krass
CAC. L. Armour
C. L. Armour
BMB. Mitchell
B. Mitchell
MBM. Brillant
M. Brillant
RDR. Dienaar
R. Dienaar
Jenny WilkinsonJenny Wilkinson
Jenny Wilkinson

1 February 1998 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
LHL Hodge
L Hodge
CSCm Salome
Cm Salome
JHJm Hughes
Jm Hughes
DLD Liu-Brennan
D Liu-Brennan
JRJ Rimmer
J Rimmer
AWAj Woolcock
Aj Woolcock
We assessed the clinical and biochemical effects in asthmatic children of fish oil supplementation and a diet that increases omega-3 and reduces omega-6 fatty acids. Thirty nine asthmatic children aged 8-12 yrs participated in a double-blind, randomized, controlled trial for 6 months during which they received fish oil capsules plus canola oil and margarine (omega-3 group) or safflower oil capsules plus sunflower oil and margarine (omega-6 group). Plasma fatty acids, stimulated tumour necrosis factor alpha (TNFalpha) production, circulating eosinophil numbers and lung function were measured at baseline and after 3 and 6 months of dietary modification. Day and night symptoms, peak flow rates and medication use were recorded for 1 week prior to laboratory visits. Plasma phospholipid omega-3 fatty acids were significantly greater in the omega-3 group at 3 and 6 months compared to the omega-6 group (p<0.001). In the omega-3 group TNFalpha production fell significantly compared with baseline (p=0.026), but the magnitude of change between groups did not reach significance (p=0.075). There were no significant changes in clinical outcome measures. Dietary enrichment of omega-3 fatty acids over 6 months increased plasma levels of these fatty acids, reduced stimulated tumour necrosis factor alpha production, but had no effect on the clinical severity of asthma in these children.

1 August 2014 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
MUMd Ashik Ullah
Md Ashik Ullah
ZLZhixuan Loh
Zhixuan Loh
WGWan Jun Gan
Wan Jun Gan
VZVivian Zhang
Vivian Zhang
HYHuan Yang
Huan Yang
MSMaria Sukkar
Maria Sukkar